固体脂质纳米载体(SLN)为乳腺癌治疗提供了一个有希望的途径,一种占全球癌症病例12.5%的疾病。尽管联合疗法取得了长足的进步(手术,化疗,辐射,和内分泌治疗),像全身毒性这样的挑战,耐药性,不利影响持续存在。该手稿通过使用SLN为乳腺癌治疗领域提供了一些新的贡献,这些是创新的药物输送系统,多功能性,和生物相容性,克服抗药性的潜力,与新兴疗法的整合,专注于个性化医疗,正在进行和未来的研究方向和减少副作用的潜力。SLN由于其独特的物理化学性质而提出了一种新颖的策略。它们可以封装亲水性和疏水性药物,确保控制释放和定向递送,从而提高溶解度和生物利用度并减少副作用。SLN的多功能性质改善了药物递送,同时它们的生物相容性支持了它们在癌症治疗中的潜力。药剂师面临的挑战包括保持稳定,有效载药量,和定时交货。将SLN与基因和免疫疗法等新兴疗法相结合,有望获得更有效的乳腺癌治疗。SLN代表着重大进步,提供精确的药物输送和更少的副作用,具有克服耐药性的潜力。正在进行的研究将改进乳腺癌治疗的SLN,靶向细胞,副作用最小,并与其他治疗相结合,以获得全面的方法。纳米技术和个性化医学的进步将使SLN适应特定的乳腺癌亚型,增强有效性。临床试验和新的治疗开发对于实现SLN在乳腺癌治疗中的全部潜力至关重要。总之,SLN为乳腺癌治疗提供了一种变革性的方法,解决药物输送和副作用的问题。正在进行的研究旨在优化SLN的靶向治疗,有可能彻底改变乳腺癌护理,为患者提供希望。
Solid Lipid
Nanocarriers (SLNs) offer a promising avenue for breast cancer treatment, a disease that accounts for 12.5% of global cancer cases. Despite strides in combined therapies (surgery, chemotherapy, radiation, and endocrine therapy), challenges like systemic toxicity, drug resistance, and adverse effects persist. The manuscript offers several novel contributions to the field of breast cancer treatment through the use of SLNs, and these are innovative drug delivery systems, multifunctionality, and biocompatibility, the potential to overcome drug resistance, integration with emerging therapies, focus on personalized medicine, ongoing and future research directions and potential for reduced side effects. SLNs present a novel strategy due to their unique physicochemical properties. They can encapsulate both hydrophilic and hydrophobic drugs, ensuring controlled release and targeted delivery, thus enhancing solubility and bioavailability and reducing side effects. The multifunctional nature of SLNs improves drug delivery while their biocompatibility supports their potential in cancer therapy. Challenges for pharmacists include maintaining stability, effective drug loading, and timed delivery. Combining SLNs with emerging therapies like gene and immunotherapy holds promise for more effective breast cancer treatments. SLNs represent a significant advancement, providing precise drug delivery and fewer side effects, with the potential for overcoming drug resistance. Ongoing research will refine SLNs for breast cancer therapy, targeting cells with minimal side effects and integrating with other treatments for comprehensive approaches. Advances in nanotechnology and personalized medicine will tailor SLNs to specific breast cancer subtypes, enhancing effectiveness. Clinical trials and new treatment developments are crucial for realizing SLNs\' full potential in breast cancer care. In conclusion, SLNs offer a transformative approach to breast cancer treatment, addressing issues of drug delivery and side effects. Ongoing research aims to optimize SLNs for targeted therapy, potentially revolutionizing breast cancer care and providing hope for patients.